Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
Amarin’s (AMRN) stock price could move most on an event not happening — that is, if the FDA decides not to schedule an advisory committee meeting to review Vascepa, the company’s heart drug derived from fish oil. Amarin is seeking approval for an expansion of the Vascepa label to include data from a large clinical trial that showed a 25% reduction in the risk of bad cardiovascular events like heart attack and strokes.
About the Author Reprints
